MRNA fell -7.02% during regular market hours on Tuesday, retreating to $74.17 from a prior close of $79.77, as the stock gave back a portion of its recent explosive rally. The decline represents profit-taking after shares surged more than +70% over the past month and hit a 52-week high of $85.60 on July 6, driven by a unanimous 9-0 FDA advisory panel vote backing the company's mRNA flu vaccine.

Tango Therapeutics shares surged approximately 49% over the past 30 days, driven by groundbreaking Phase 1/2 clinical trial results for its lead PRMT5 inhibitor, vopimetostat. The vopimetostat plus daraxonrasib combination achieved a 92% objective response rate in heavily pre-treated MTAP-deleted pancreatic cancer patients, with a 90% six-month progression-free survival rate.

ORKA shares surged approximately 31.9% over the last 30 days, climbing from $64.06 on June 8 to $84.50 on July 7, 2026. The rally was fueled by a major collaboration with Halozyme to develop ORKA-001 using Hypercon™ technology, a $700 million follow-on offering that strengthened the balance sheet, and a series of analyst upgrades and price target increases.

Corcept Therapeutics shares surged approximately 28.3% over the last 30 days, climbing from $72.62 to $93.16, driven by the resubmission of its New Drug Application for relacorilant in Cushing's syndrome. The stock has posted an extraordinary quarterly gain of roughly 123.5%, reflecting a powerful rally that began in early May following the Lifyorli approval in ovarian cancer and accelerating through June.

CRNX shares surged +98.69% in pre-market trading on Tuesday, reaching $83.51 after Vertex Pharmaceuticals announced a definitive agreement to acquire the company for $85 per share in cash. The all-cash deal values Crinetics at approximately $10 billion in equity, representing a 102% premium to Monday's closing price of $42.03.

AKTS plunged -16.28% during Monday's regular trading session, falling from Friday's close of $31.76 to $26.59, erasing a significant portion of recent gains. The sell-off follows a powerful rally that saw the stock surge over +40% in the prior two weeks, hitting a new 52-week high above $34, suggesting profit-taking as the primary driver.

SLBT shares fell -21.20% to $4.72 during Monday's regular session, erasing a large portion of the +34.6% surge recorded on July 2 before the Independence Day holiday. The decline represents a sharp mean-reversion move with no specific company news or fundamental catalyst, following a five-session rally that had added +59.7% through last Thursday's close.

VRTX surged 24.2% over the past 30 days, driven by renewed investor confidence in its pipeline. The stock's quarterly gain of approximately 9.9% reflects a steady uptrend that accelerated in late June.

TG Therapeutics (TGTX) surged approximately 45.7% over the last 30 days, climbing from $36.64 on June 2 to $53.37 by July 2, 2026. The rally extended a powerful quarterly uptrend, with the stock gaining roughly 59% since the start of April 2026.

Kymera Therapeutics shares surged approximately 55.1% over the last 30 days, driven by a series of positive clinical and corporate catalysts. The pivotal event was the early completion of enrollment in the Phase 2b BROADEN2 trial for KT-621 in atopic dermatitis, accelerating the topline data readout to year-end 2026.

Apogee Therapeutics shares surged approximately 68.9% over the past 30 days, driven almost entirely by AbbVie's announced $10.9 billion all-cash acquisition. AbbVie agreed to pay $135.11 per share, representing a 49.5% premium to Apogee's closing price before the deal was revealed.

Bio-Techne shares surged approximately 42.3% over the last 30 days, driven overwhelmingly by Merck KGaA's announced $73-per-share all-cash acquisition. The $11.3 billion enterprise value deal, unveiled on June 25, 2026, represented a 24% premium to Bio-Techne's prior closing price and triggered a single-day rally of roughly 20%.

Moderna shares surged approximately 74.9% over the past 30 days, climbing from $45.64 on June 2 to $79.80 by July 2, 2026, driven by a series of powerful pipeline and regulatory catalysts. A unanimous 9-0 FDA advisory committee vote in favor of the company's mRNA-1010 flu vaccine candidate dramatically de-risked a key commercial opportunity ahead of the August 5 PDUFA decision.

UNCY shares tumbled -34.22% on Tuesday, falling from a previous close of $7.13 to $4.69, after the FDA issued a second Complete Response Letter for its kidney disease drug candidate oxylanthanum carbonate. The selloff ignited in premarket trading and intensified during the regular session, with intraday losses briefly exceeding -46% before a partial recovery into the close.

NVCT shares are trading approximately 22% lower in premarket on June 30, 2026, following the overnight pricing of a deeply discounted equity offering. The primary catalyst is Nuvectis Pharma's pricing of a $100 million underwritten public offering of 5 million shares at $20.00 each — a roughly 30% discount to the prior session's closing price of $28.53.

OMER shares are plunging approximately 26% in premarket trading on Friday, June 26, 2026, from a prior close of $10.72 to around $7.93. The primary catalyst is a negative opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which rejected the marketing authorization application for narsoplimab (YARTEMLEA) in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in Europe.

SPRY shares plunged approximately 26% in premarket trading on June 25, 2026, falling from the prior session's close of $10.54 to roughly $7.80. The primary catalyst was a late Wednesday commercial update confirming no new commercial formulary additions for neffy (epinephrine nasal spray) in the July 1, 2026 payer coverage cycle — a significant miss against market expectations.

SYRE shares are down approximately 10.87% in premarket trading on Wednesday, June 24, 2026, extending a decline that began in the prior regular session. The selloff follows a period of sharp appreciation driven by positive clinical trial data, with profit-taking accelerating as the stock hit multi-month highs and insider lock-up expirations from the April 2026 equity offering came into focus.

APGE surged +46.75% to $132.63 during regular market hours from a prior close of $90.38. Primary catalyst was AbbVie’s $10.9 billion cash acquisition announcement.

Shares of Definium Therapeutics (DFTX) surged approximately 55% in premarket trading on Monday, June 22, 2026, following a landmark clinical data readout. The primary catalyst is a positive Phase 3 Emerge trial result for DT120 ODT — an LSD-based orally disintegrating tablet — which met its primary endpoint with high statistical significance (p<0.0001) in treating major depressive disorder.